循环microRNAs在乳腺癌诊治中的应用
The Diagnostic and Therapeutic Application of Circulating microRNAs in Breast Cancer
DOI: 10.12677/MD.2015.53010, PDF, HTML, XML, 下载: 2,578  浏览: 7,810 
作者: 薛丽：海南医学院科学实验中心，海南 海口；白玉杰*：海南医学院海南省干细胞研究所，海南 海口
关键词: 微小核糖核酸；乳腺癌；生物标志；诊断；治疗；microRNA； Breast Cancer； Biomarker； Diagnosis； Therapy
摘要: 微小核糖核酸(microRNAs, miRNAs)是一类具有调控功能的小分子非编码核糖核酸，与肿瘤的发生有密切关系。大量研究也充分证实了miRNAs在乳腺癌中的作用。循环miRNAs (circulating miRNAs)指存在于血液或其他体液中的细胞外游离microRNAs，具有稳定性好、取材方便、创伤小，可反复取样检测等优点，且与肿瘤发生和发展相关，因此被认为是最具潜力的肿瘤标志之一。本综述主要总结循环miRNAs在乳腺癌早期诊断、预后预测及指导治疗等方面研究及其临床应用进展，并探讨循环miRNAs临床应用所面临的挑战和需解决的问题。
Abstract: MicroRNAs (miRNAs) are a class of short non-coding regulatory RNAs with an etiological contribution to carcinogensis. The involvement of miRNAs in breast cancer has been reiterated and irrefutably proved by many studies. Circulating miRNAs refer to the cell free miRNAs in the blood or other body fluids, with characteristics such as remarkable stability, ease of access, minimal invasiveness, possibility of repeated sampling, and proven roles in cancer development and progression, so it has been regarded as one of the most potential biomarkers of tumor. This review focuses on recent-finding of circulating miRNAs as biomarkers in early diagnostic, prognostic indications and treatment selection, along with an appraisal of the translational implication of this field. We also addressed the future and the problems and challenges that need to be overcome to achieve clinical implementation of circulating miRNAs.
文章引用：薛丽, 白玉杰. 循环microRNAs在乳腺癌诊治中的应用[J]. 医学诊断, 2015, 5(3): 47-53. http://dx.doi.org/10.12677/MD.2015.53010

参考文献

[1] Le, M.T., Hamar, P., Guo, C.Y., Basar, E., Perdigão-Henriques, R., Balaj, L. and Lieberman, J. (2014) miR-200- containing extracellular vesicles promote breast cancer cellmetastasis. The Journal of Clinical Investigation, 124, 5109-5128.
http://dx.doi.org/10.1172/JCI75695
[2] Bovy, N., Blomme, B., Frères, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J.A., Noël, A., Thiry, M., Jérusalem, G., Josse, C., Bours, V., Tabruyn, S.P. and Struman, I. (2015) Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget, 6, 10253-10266.
[3] Cookson, V.J., Bentley, M.A., Hogan, B.V., Horgan, K., Hayward, B.E., Hazelwood, L.D. and Hughes, T.A. (2012) Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cellular Oncology, 35, 301-308.
http://dx.doi.org/10.1007/s13402-012-0089-1
[4] Si, H.Y., Sun, X.M., Chen, Y.J., Cao, Y., Chen, S.M., Wang, H.C. and Hu, C.J. (2013) Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. Journal of Cancer Research and Clinical Oncology, 139, 223-229.
http://dx.doi.org/10.1007/s00432-012-1315-y
[5] Roth, C., Rack, B., Müller, V., Janni, W., Pantel, K. and Schwarzenbach, H. (2010) Circulating microRNAs as blood- based markers for patients with primary and metastatic breast cancer. Breast Cancer Research, 12, R90.
http://dx.doi.org/10.1186/bcr2766
[6] Schwarzenbach, H, Milde-Langosch, K., Steinbach, B., Müller, V. and Pantel, K. (2012) Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Research and Treatment, 134, 933-941.
http://dx.doi.org/10.1007/s10549-012-1988-6
[7] Gao, J., Zhang, Q., Xu, J., Guo, L. and Li, X. (2013) Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chinese Journal of Cancer Research, 25, 743-748.
[8] Liu, L.H., Wang, S., Cao, X.T. and Liu, J.C. (2014) Analysis of circulating microRNA biomarkers for breast cancer detection: A meta-analysis. Tumor Biology, 35, 12245-12253.
http://dx.doi.org/10.1007/s13277-014-2533-5
[9] Kodahl, A.R., Lyng, M.B., Binder, H., Cold, S., Gravgaard, K., Knoop, A.S. and Ditzel, H.J. (2014) Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Molecular Oncology, 8, 874-883.
http://dx.doi.org/10.1016/j.molonc.2014.03.002
[10] Cuk, K., Zucknick, M., Heil, J., Madhavan, D., Schott, S., Turchinovich, A., et al. (2013) Circulating microRNAs in plasma as early detection markers for breast cancer. International Journal of Cancer, 32, 1602-1612.
http://dx.doi.org/10.1002/ijc.27799
[11] Madhavan, D., Zucknick, M., Wallwiener, M., Cuk, K., Modugno, C., Scharpff, M., Schott, S., Heil, J., Turchinovich, A., Yang, R.X., Benner, A., Riethdorf, S., Trumpp, A., Sohn, C., Pantel, K., Schneeweiss, A. and Burwinkel, B. (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clinical Cancer Research, 18, 5972-5982.
http://dx.doi.org/10.1158/1078-0432.CCR-12-1407
[12] Kleivi Sahlberg, K., Bottai, G., Naume, B., Burwinkel, B., Calin, G.A., Børresen-Dale, A.L. and Santarpia, L. (2015) A serum microRNA signature predicts tumor relapse and survival in triple-negativebreast cancer patients. Clinical Cancer Research, 21, 1207-1214.
[13] Eichelser, C., Stückrath, I., Müller, V., Milde-Langosch, K., Wikman, H., Pantel, K. and Schwarzenbach, H. (2014) Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget, 5, 9650-9663.
[14] Jung, E.J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., Di Leo, A., Le, X.F., Bast Jr., R.C., Park, S.T., Pusztai, L. and Calin, G.A. (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118, 2603-2614.
http://dx.doi.org/10.1002/cncr.26565
[15] Sun, Y., Wang, M.G., Lin, G.J., Sun, S.P., Li, X.X., Qi, J. and Li, J.M. (2012) Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS ONE, 7, e47003.
http://dx.doi.org/10.1371/journal.pone.0047003
[16] Anfossi, S., Giordano, A., Gao, H., Cohen, E.N., Tin, S., Wu, Q., et al. (2014) High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS ONE, 9, e83113.
http://dx.doi.org/10.1371/journal.pone.0083113
[17] Eroles, P., Tormo, E., Pineda, B., Espin, E. and Lluch, A. (2015) MicroRNAs in breast cancer: one more turn in regulation. Current Drug Targets, (Epub Ahead of Print).
[18] Heneghan, H.M., Miller, N., Lowery, A.J., Sweeney, K.J., Newell, J. and Kerin, M.J. (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of Surgery, 251, 499-505.
[19] Li, Q., Liu, M., Ma, F., Luo, Y., Cai, R.G., Wang, L.M., Xu, N.Z. and Xu, B.H. (2014) Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal Asubtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS ONE, 9, e104870.
[20] Jung, E.J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., et al. (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118, 2603-2614.
http://dx.doi.org/10.1002/cncr.26565
[21] Müller, V., Gade, S., Steinbach, B., Loibl, S., von Minckwitz, G., Untch, M., Schwedler, K., Lübbe, K., Schem, C., Fasching, P.A., Mau, C., Pantel, K. and Schwarzenbach, H. (2014) Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: A translational research project within the Geparquinto trial. Breast Cancer Research and Treatment, 147, 61-68.
http://dx.doi.org/10.1007/s10549-014-3079-3
[22] Ward, A., Shukla, K., Balwierz, A., Soons, Z., König, R., Sahin, O., et al. (2014) MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. The Journal of Pathology, 233, 368-379.
http://dx.doi.org/10.1002/path.4363
[23] Zhao, H., Shen, J., Medico, L., Wang, D., Ambrosone, C.B. and Liu, S. (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE, 5, e13735
[24] Erbes, T., Hirschfeld, M., Rücker, G., Jaeger, M., Boas, J., Iborra, S., Mayer, S., Gitsch, G. and Stickeler, E. (2015) Feasibility of urinary microRNA detection in breast cancer patients and itspotential as an innovative non-invasive biomarker. BMC Cancer, 15, 193.
http://dx.doi.org/10.1186/s12885-015-1190-4
[25] Asaga, S. and Hoon, D.S. (2013) Direct serum assay for microRNA in cancer patients. Methods in Molecular Biology, 1024, 147-155.
http://dx.doi.org/10.1007/978-1-62703-453-1_11